tiprankstipranks
TipRanksStock Market NewsH.C. Wainwright Thinks Arcadia Biosciences’ Stock is Going to Recover
Blurbs

H.C. Wainwright Thinks Arcadia Biosciences’ Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arcadia Biosciences (RKDAResearch Report), with a price target of $6.00. The company’s shares closed last Friday at $1.04, close to its 52-week low of $0.99.

According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $5.25.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $6.40 and a one-year low of $0.99. Currently, Arcadia Biosciences has an average volume of 386.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcadia Biosciences, Inc. is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. The company’s portfolio of agricultural productivity traits includes Nitrogen Use Efficiency, Water Use Efficiency, Drought Tolerance, Salinity Tolerance and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.

Read More on RKDA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More